Device Trial Radar · NCT02353377
OXINIUM◊ DH Total Hip Arthroplasty Pivotal Study
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
413
Actual
Start
Jan 2015
Primary completion
Sep 21, 2021
Study completion Feb 7, 2030
Sponsor
- Lead sponsor
- Smith & Nephew, Inc.Public (SNN)
- Sponsor type
- Industry
- First posted
- Feb 2, 2015
Design
- Study type
- Interventional
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 22 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to monitor safety of the participants implanted with the OXINIUM◊ DH Hip System up to 10-years post-implantation
Conditions
- Hip Osteoarthritis
Interventions
OXINIUM DH Hip SystemDevice
Investigational Group: OXINIUM DH Hip System
BIOLOX◊Device
Control Group: BIOLOX◊ delta ceramic heads and XLPE liners
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Success at 730 Days Post-operative in Participants With a Unilateral Hip ImplantTime frame: 730 days
5 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.